
codex
**G1 verdict: FAIL.** V2 establishes a computable, panel-conditional **descriptive association**, but still does not establish the transfer question it claims to test. This failure concerns identification and evidence—not unfinished Lock-1 implementation or the broader project’s completion criteria.

I read all requested materials. Independent Broad checks reproduced the matrix dimensions, contrast counts, selection exclusions, sign-flip statistics, direction checks, and raw correlation. All 18 manifested files match their recorded sizes and SHA-256 hashes and the saved Figshare responses’ file checksums. Live Figshare API verification was unavailable. No quarantined Sanger outcomes were parsed or displayed, and no edits were made.

1. **R1-1 [CRITICAL] Operational estimand — PARTIALLY RESOLVED.**  
   [Question v2](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/reviews/g1_question_v2.md:10) now defines `T_g = |MeanDifference_g|` and a partial Spearman association. The raw association reproduces exactly: **ρ = 0.1668304275**.

   However, absolute organoid–adherent **mean dependency difference is not loss of predictive transfer**. A relationship can transfer perfectly despite a mean shift, or fail without one. The external endpoint remains “**continuous corrected LFC ranking endpoint, exact form at Lock 1**.” Its reference, comparator, and numerical transfer-loss quantity are still unspecified. Those are identification choices, not merely implementation details.

2. **R1-2 [CRITICAL] Selection circularity — PARTIALLY RESOLVED.**  
   [Provenance v2](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/provenance_v2.md:18) reports “**26/250 panel genes are direct 200-outlier members**.” I independently reproduced the exact 26-gene exclusion list using the specified tails.

   The restriction “**Broad-side associations are development/descriptive evidence only**” is appropriate. Nevertheless, pathway-level selection remains, and the primary response still comes from the comparison that informed panel construction. Excluding direct tail members does not make the remaining association selection-independent. Circularity is adequately contained **for a descriptive development statistic**, but not resolved for the claimed independent transfer finding. Donor-disjoint external evidence remains unestablished.

3. **R1-3 [CRITICAL] Preprocessing independence — PARTIALLY RESOLVED.**  
   The audit now identifies concrete transformations, but its conclusion that Sanger matrices are “**not development-independent by construction**” is too strong. The [author pipeline](https://raw.githubusercontent.com/Garnett-Lab/SangerOrganoidBiobank/main/scripts/CRISPR_pipeline.R) computes cross-sample mean LFCs for spline correction and applies ComBat across libraries. This establishes outcome-dependent coupling within the processed cohort; it does **not**, by itself, establish influence on Broad development artifacts.

   The missing evidence remains the actual fitting populations and artifact dependencies across the development/evaluation boundary. Conversely, merely “downgrading independence” cannot repair genuine cross-boundary leakage. The Broad minipool processing description also remains insufficient to identify its fitted parameter dependencies.

4. **R1-4 [HIGH] Independent-unit counts and weighting — RESOLVED for the counting error.**  
   [The audit](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/identifiability_audit.json:1) correctly reports **5 medium pairs/4 models** and **7 format pairs/6 models**. Both reproduce. Question v2 explicitly averages ACH-003040’s two contrasts before assigning equal model weights.

   “**Donors … UNRESOLVED**” appropriately prevents equating six models with six verified independent donors. Donor ascertainment remains an external-eligibility requirement, but the original counting and weighting mistake is corrected.

5. **R1-5 [HIGH] Unsupported heterogeneity interpretation — PARTIALLY RESOLVED.**  
   [Provenance v2](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/provenance_v2.md:14) explicitly says “**heterogeneity dominates / averages near-uninterpretable … retracted**.” The test/control sign-flip and magnitude statistics reproduce.

   Yet the still-operative [novelty audit](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/reviews/novelty_audit_v1.md:15) continues to assert “**per-gene average deltas hide extreme heterogeneity**,” using the same sign flips to motivate context stratification. The correction has not propagated through the package. Technical-noise calibration also remains absent.

6. **R1-6 [HIGH] Observation provenance and attrition — PARTIALLY RESOLVED.**  
   The new [35-row registry](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/observation_provenance_minipool.csv:1) materially improves replicate, condition, QC, and laboratory documentation. Missing lineage for ACH-003052 is explicitly acknowledged and appropriately limits lineage-conditioned claims.

   However, donor identities and biological sample origins remain incomplete, and missing condition combinations are not individually registered with their disposition. More seriously, “**1 replicate removed**” conflicts with the released sequence metadata, which flags **two** excluded replicates:

   - `0178_Adh_Alt_SF_Dome_RepA`
   - `0178_Adh_Nat_Serum_Dome_RepB`

   The registry copies both exclusion flags but annotates only the latter. Screen-level read totals include both flagged replicates’ reads. This requires reconciliation of QC summaries versus actual scoring inputs; it does not establish which replicates entered Chronos.

7. **R1-7 [HIGH] Treatment scope and confounding — RESOLVED.**  
   [V2](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/provenance_v2.md:9) correctly names the full medium-composition and plastic–Matrigel-dome bundles. Question v2 explicitly rejects “**causal explanation of transfer failure**” and isolated geometry/serum claims. Restricting interpretation to observed within-model comparisons is appropriate.

8. **R1-8 [HIGH] Sanger validation outcome identity — UNRESOLVED.**  
   The package now correctly distinguishes binary BAGEL calls from continuous outcomes. But [provenance v2](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/provenance_v2.md:23) still says the continuous matrix is “**not downloaded**,” while cohort identity, crosswalks, coverage, and duplicate-library disposition remain future work.

   Naming Passports/Miner and locating a continuous-file entry establishes a plausible route, not a demonstrated joinable evaluation cohort. Schema and identifier verification can proceed without inspecting quarantined outcome values; it has not yet been supplied.

9. **R1-9 [HIGH] Exposure disposition — RESOLVED for the documented 18-cell event.**  
   [The exposure log](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/exposure_log.jsonl:4) now names the three genes and six models. Independent Broad metadata checks confirm all six models have `IsTraditional2D=True`; none of the three genes belongs to the 250-gene panel.

   That supports retaining the candidate organoid evaluation rather than discarding the resource. It supports the narrow conclusion that the **listed exposed cells are outside the eligible target panel**. It does not certify that public outcomes were globally unknowable or that an as-yet-unresolved cohort is genuinely blinded.

10. **R1-10 [HIGH] Layer-B reuse — PARTIALLY RESOLVED.**  
    [Partitions v2](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/partitions_provisional.json:8) correctly labels inspected-data reuse “**reused-data engineering evaluation**.”

    However, “**task definitions for FRESH Phase-5 rollouts**” does not itself establish reserved biological evidence. New rollouts can generate new engineering outcomes while reusing known biological rewards. No actual reserved panel membership is demonstrated. This remains a policy-evaluation limitation, not an independent reason to fail the scientific G1 gate.

11. **R1-11 [HIGH] Precise novelty — UNRESOLVED.**  
    The [novelty audit](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/reviews/novelty_audit_v1.md:13) still says “**Nobody has tested**,” retains the rejected heterogeneity rationale, and lists supplement/code reads as “**Open items for G1 gate**.”

    More fundamentally, its proposed gap concerns environmental sensitivity versus **transfer degradation**, whereas the implemented statistic concerns environmental measurements versus **cohort mean differences**. That narrower descriptive relationship needs its own comparison against S1’s analyses. The current audit does not establish it as a distinct unresolved contribution.

12. **R1-12 [HIGH] Falsification, precision, and δ — PARTIALLY RESOLVED.**  
    The `SIGNAL`/`BOUND`/`INCONCLUSIVE` rules are substantially clearer. The [precision artifact](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/precision_feasibility_v1.json:14) honestly states that its model bootstrap captures “**environmental-side uncertainty only**.”

    Nevertheless:

    - The supplied interval **[0.00834, 0.24742] concerns raw ρ**, while the primary parameter is partial ρ.
    - It straddles δ = 0.20 and establishes neither a signal nor a bound.
    - No eligible external donor count or external-endpoint precision calculation is supplied.
    - Interval width alone does not establish that a meaningful signal is infeasible.
    - A bound below **+0.20** excludes a sufficiently large positive association; it does not establish weak association in both directions.

    **δ = 0.20 may remain a candidate for Lock 1, but its present justification is inadequate.** “Would not change target-trust decisions” lacks a specified decision rule. S3’s prediction–outcome correlations measure something different from this across-gene explanatory association. Finalizing δ later is permissible; treating its scientific relevance or attainability as established now is not.

13. **R1-13 [MEDIUM] Manifest completeness and reproducibility — PARTIALLY RESOLVED.**  
    Both formerly omitted Sanger files are now manifested. Saved authoritative responses include version and license information, and all 18 local files match their records. The revised audit code independently reproduces the reported direction checks and descriptive statistics.

    Remaining gaps include missing per-entry article versions for **9/13 Broad entries**, unpinned processing-code revisions, and no supplied regeneration procedure for the precision artifact. The documented QC discrepancy is useful, but the stated screen-read range “**6.7M–59M**” is incorrect: the released maximum is **88,316,766**.

The additional issues are consequential:

- **The claimed common reference population is inaccurate.** Among the 223 joined genes, 215 have `AdherentN=433`; five have **9**, two have **145**, and one has **432**. Thus the primary response mixes differently supported reference comparisons. Eligibility and uncertainty must address this explicitly.
- **The claimed TMOD attrition is not established.** The table contains `TMOD1 (7111)`, and [NCBI documents `TMOD` as its alias](https://www.ncbi.nlm.nih.gov/gene/7111/). The library guides require identifier adjudication before calling this missing outcome coverage. **223 exact-symbol joins is verified; 223 as the scientifically correct eligible population is provisional.**
- **The lability operator changed from the unstick recommendation.** Unstick averages absolute medium-specific changes; v2 takes the absolute value after averaging those changes within a model. These differ for **111/223 genes**, allowing opposing changes in ACH-003040 to cancel. Either can define a descriptive score, but they answer different questions.
- **“Partial Spearman” needs an exact definition.** The reported **0.085695** reproduces by correlating re-ranked rank residuals. Pearson correlation of the rank residuals gives **0.083961**. This small discrepancy is suitable for Lock-1 clarification, but the accompanying variance-explained argument must match the chosen operation.
- **The fallback changes the question again.** A “within-Broad environmental bound” does not follow automatically from an upper bound on association with absolute cohort mean differences. It cannot bound the causal contribution of culture or latent biological sensitivity.

**Operational and joinable:** yes, for the narrowly defined descriptive Broad statistic, subject to identifier adjudication and heterogeneous reference coverage. **Circularity:** appropriately disclosed for development description, inadequately controlled for independent confirmation. **Precision:** limitations are disclosed, but primary and external feasibility remain undemonstrated. **δ:** provisional, with insufficient decision justification.

A G1 pass does not require completed external evaluation or finalized Lock-1 machinery. It does require one coherent, plausibly novel question with a demonstrated evidence route. V2 still alternates among cohort mean shift, unspecified ranking transfer, and an environmental bound. The [unstick review](/Users/bmarti44/github/bufferright/research/reviews/unstick_g1.md:15) explicitly warned: “**A correlation between minipool effects and the downloaded Broad group-comparison table … cannot clear the independent-transfer gate.**” V2 has implemented that development correlation without resolving the distinction.

SCORE: 70
tokens used
95,525
**G1 verdict: FAIL.** V2 establishes a computable, panel-conditional **descriptive association**, but still does not establish the transfer question it claims to test. This failure concerns identification and evidence—not unfinished Lock-1 implementation or the broader project’s completion criteria.

I read all requested materials. Independent Broad checks reproduced the matrix dimensions, contrast counts, selection exclusions, sign-flip statistics, direction checks, and raw correlation. All 18 manifested files match their recorded sizes and SHA-256 hashes and the saved Figshare responses’ file checksums. Live Figshare API verification was unavailable. No quarantined Sanger outcomes were parsed or displayed, and no edits were made.

1. **R1-1 [CRITICAL] Operational estimand — PARTIALLY RESOLVED.**  
   [Question v2](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/reviews/g1_question_v2.md:10) now defines `T_g = |MeanDifference_g|` and a partial Spearman association. The raw association reproduces exactly: **ρ = 0.1668304275**.

   However, absolute organoid–adherent **mean dependency difference is not loss of predictive transfer**. A relationship can transfer perfectly despite a mean shift, or fail without one. The external endpoint remains “**continuous corrected LFC ranking endpoint, exact form at Lock 1**.” Its reference, comparator, and numerical transfer-loss quantity are still unspecified. Those are identification choices, not merely implementation details.

2. **R1-2 [CRITICAL] Selection circularity — PARTIALLY RESOLVED.**  
   [Provenance v2](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/provenance_v2.md:18) reports “**26/250 panel genes are direct 200-outlier members**.” I independently reproduced the exact 26-gene exclusion list using the specified tails.

   The restriction “**Broad-side associations are development/descriptive evidence only**” is appropriate. Nevertheless, pathway-level selection remains, and the primary response still comes from the comparison that informed panel construction. Excluding direct tail members does not make the remaining association selection-independent. Circularity is adequately contained **for a descriptive development statistic**, but not resolved for the claimed independent transfer finding. Donor-disjoint external evidence remains unestablished.

3. **R1-3 [CRITICAL] Preprocessing independence — PARTIALLY RESOLVED.**  
   The audit now identifies concrete transformations, but its conclusion that Sanger matrices are “**not development-independent by construction**” is too strong. The [author pipeline](https://raw.githubusercontent.com/Garnett-Lab/SangerOrganoidBiobank/main/scripts/CRISPR_pipeline.R) computes cross-sample mean LFCs for spline correction and applies ComBat across libraries. This establishes outcome-dependent coupling within the processed cohort; it does **not**, by itself, establish influence on Broad development artifacts.

   The missing evidence remains the actual fitting populations and artifact dependencies across the development/evaluation boundary. Conversely, merely “downgrading independence” cannot repair genuine cross-boundary leakage. The Broad minipool processing description also remains insufficient to identify its fitted parameter dependencies.

4. **R1-4 [HIGH] Independent-unit counts and weighting — RESOLVED for the counting error.**  
   [The audit](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/identifiability_audit.json:1) correctly reports **5 medium pairs/4 models** and **7 format pairs/6 models**. Both reproduce. Question v2 explicitly averages ACH-003040’s two contrasts before assigning equal model weights.

   “**Donors … UNRESOLVED**” appropriately prevents equating six models with six verified independent donors. Donor ascertainment remains an external-eligibility requirement, but the original counting and weighting mistake is corrected.

5. **R1-5 [HIGH] Unsupported heterogeneity interpretation — PARTIALLY RESOLVED.**  
   [Provenance v2](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/provenance_v2.md:14) explicitly says “**heterogeneity dominates / averages near-uninterpretable … retracted**.” The test/control sign-flip and magnitude statistics reproduce.

   Yet the still-operative [novelty audit](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/reviews/novelty_audit_v1.md:15) continues to assert “**per-gene average deltas hide extreme heterogeneity**,” using the same sign flips to motivate context stratification. The correction has not propagated through the package. Technical-noise calibration also remains absent.

6. **R1-6 [HIGH] Observation provenance and attrition — PARTIALLY RESOLVED.**  
   The new [35-row registry](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/observation_provenance_minipool.csv:1) materially improves replicate, condition, QC, and laboratory documentation. Missing lineage for ACH-003052 is explicitly acknowledged and appropriately limits lineage-conditioned claims.

   However, donor identities and biological sample origins remain incomplete, and missing condition combinations are not individually registered with their disposition. More seriously, “**1 replicate removed**” conflicts with the released sequence metadata, which flags **two** excluded replicates:

   - `0178_Adh_Alt_SF_Dome_RepA`
   - `0178_Adh_Nat_Serum_Dome_RepB`

   The registry copies both exclusion flags but annotates only the latter. Screen-level read totals include both flagged replicates’ reads. This requires reconciliation of QC summaries versus actual scoring inputs; it does not establish which replicates entered Chronos.

7. **R1-7 [HIGH] Treatment scope and confounding — RESOLVED.**  
   [V2](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/provenance_v2.md:9) correctly names the full medium-composition and plastic–Matrigel-dome bundles. Question v2 explicitly rejects “**causal explanation of transfer failure**” and isolated geometry/serum claims. Restricting interpretation to observed within-model comparisons is appropriate.

8. **R1-8 [HIGH] Sanger validation outcome identity — UNRESOLVED.**  
   The package now correctly distinguishes binary BAGEL calls from continuous outcomes. But [provenance v2](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/provenance_v2.md:23) still says the continuous matrix is “**not downloaded**,” while cohort identity, crosswalks, coverage, and duplicate-library disposition remain future work.

   Naming Passports/Miner and locating a continuous-file entry establishes a plausible route, not a demonstrated joinable evaluation cohort. Schema and identifier verification can proceed without inspecting quarantined outcome values; it has not yet been supplied.

9. **R1-9 [HIGH] Exposure disposition — RESOLVED for the documented 18-cell event.**  
   [The exposure log](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/exposure_log.jsonl:4) now names the three genes and six models. Independent Broad metadata checks confirm all six models have `IsTraditional2D=True`; none of the three genes belongs to the 250-gene panel.

   That supports retaining the candidate organoid evaluation rather than discarding the resource. It supports the narrow conclusion that the **listed exposed cells are outside the eligible target panel**. It does not certify that public outcomes were globally unknowable or that an as-yet-unresolved cohort is genuinely blinded.

10. **R1-10 [HIGH] Layer-B reuse — PARTIALLY RESOLVED.**  
    [Partitions v2](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/partitions_provisional.json:8) correctly labels inspected-data reuse “**reused-data engineering evaluation**.”

    However, “**task definitions for FRESH Phase-5 rollouts**” does not itself establish reserved biological evidence. New rollouts can generate new engineering outcomes while reusing known biological rewards. No actual reserved panel membership is demonstrated. This remains a policy-evaluation limitation, not an independent reason to fail the scientific G1 gate.

11. **R1-11 [HIGH] Precise novelty — UNRESOLVED.**  
    The [novelty audit](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/reviews/novelty_audit_v1.md:13) still says “**Nobody has tested**,” retains the rejected heterogeneity rationale, and lists supplement/code reads as “**Open items for G1 gate**.”

    More fundamentally, its proposed gap concerns environmental sensitivity versus **transfer degradation**, whereas the implemented statistic concerns environmental measurements versus **cohort mean differences**. That narrower descriptive relationship needs its own comparison against S1’s analyses. The current audit does not establish it as a distinct unresolved contribution.

12. **R1-12 [HIGH] Falsification, precision, and δ — PARTIALLY RESOLVED.**  
    The `SIGNAL`/`BOUND`/`INCONCLUSIVE` rules are substantially clearer. The [precision artifact](/Users/bmarti44/github/bufferright/research/cancer-dependency-rsi/data/precision_feasibility_v1.json:14) honestly states that its model bootstrap captures “**environmental-side uncertainty only**.”

    Nevertheless:

    - The supplied interval **[0.00834, 0.24742] concerns raw ρ**, while the primary parameter is partial ρ.
    - It straddles δ = 0.20 and establishes neither a signal nor a bound.
    - No eligible external donor count or external-endpoint precision calculation is supplied.
    - Interval width alone does not establish that a meaningful signal is infeasible.
    - A bound below **+0.20** excludes a sufficiently large positive association; it does not establish weak association in both directions.

    **δ = 0.20 may remain a candidate for Lock 1, but its present justification is inadequate.** “Would not change target-trust decisions” lacks a specified decision rule. S3’s prediction–outcome correlations measure something different from this across-gene explanatory association. Finalizing δ later is permissible; treating its scientific relevance or attainability as established now is not.

13. **R1-13 [MEDIUM] Manifest completeness and reproducibility — PARTIALLY RESOLVED.**  
    Both formerly omitted Sanger files are now manifested. Saved authoritative responses include version and license information, and all 18 local files match their records. The revised audit code independently reproduces the reported direction checks and descriptive statistics.

    Remaining gaps include missing per-entry article versions for **9/13 Broad entries**, unpinned processing-code revisions, and no supplied regeneration procedure for the precision artifact. The documented QC discrepancy is useful, but the stated screen-read range “**6.7M–59M**” is incorrect: the released maximum is **88,316,766**.

The additional issues are consequential:

- **The claimed common reference population is inaccurate.** Among the 223 joined genes, 215 have `AdherentN=433`; five have **9**, two have **145**, and one has **432**. Thus the primary response mixes differently supported reference comparisons. Eligibility and uncertainty must address this explicitly.
- **The claimed TMOD attrition is not established.** The table contains `TMOD1 (7111)`, and [NCBI documents `TMOD` as its alias](https://www.ncbi.nlm.nih.gov/gene/7111/). The library guides require identifier adjudication before calling this missing outcome coverage. **223 exact-symbol joins is verified; 223 as the scientifically correct eligible population is provisional.**
- **The lability operator changed from the unstick recommendation.** Unstick averages absolute medium-specific changes; v2 takes the absolute value after averaging those changes within a model. These differ for **111/223 genes**, allowing opposing changes in ACH-003040 to cancel. Either can define a descriptive score, but they answer different questions.
- **“Partial Spearman” needs an exact definition.** The reported **0.085695** reproduces by correlating re-ranked rank residuals. Pearson correlation of the rank residuals gives **0.083961**. This small discrepancy is suitable for Lock-1 clarification, but the accompanying variance-explained argument must match the chosen operation.
- **The fallback changes the question again.** A “within-Broad environmental bound” does not follow automatically from an upper bound on association with absolute cohort mean differences. It cannot bound the causal contribution of culture or latent biological sensitivity.

**Operational and joinable:** yes, for the narrowly defined descriptive Broad statistic, subject to identifier adjudication and heterogeneous reference coverage. **Circularity:** appropriately disclosed for development description, inadequately controlled for independent confirmation. **Precision:** limitations are disclosed, but primary and external feasibility remain undemonstrated. **δ:** provisional, with insufficient decision justification.

A G1 pass does not require completed external evaluation or finalized Lock-1 machinery. It does require one coherent, plausibly novel question with a demonstrated evidence route. V2 still alternates among cohort mean shift, unspecified ranking transfer, and an environmental bound. The [unstick review](/Users/bmarti44/github/bufferright/research/reviews/unstick_g1.md:15) explicitly warned: “**A correlation between minipool effects and the downloaded Broad group-comparison table … cannot clear the independent-transfer gate.**” V2 has implemented that development correlation without resolving the distinction.

SCORE: 70
